CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021
CTI BioPharma Corp. (NASDAQ: CTIC) will announce its second quarter 2021 financial results on August 5, 2021, post-market. A conference call and webcast will follow at 4:30 p.m. ET. Investors can join the call via phone or through the company’s website. CTI BioPharma focuses on developing therapies for blood-related cancers, particularly evaluating pacritinib for myelofibrosis treatment.
- CTI BioPharma's upcoming financial results may provide insights into growth and business progress.
- Focused on unmet medical needs in blood-related cancers, enhancing market potential.
- Dependence on a single product candidate, pacritinib, poses a risk.
- -
SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).
To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-second-quarter-2021-financial-results-on-august-5-2021-301344010.html
SOURCE CTI BioPharma Corp.
FAQ
When will CTI BioPharma announce its Q2 2021 financial results?
What time is the CTI BioPharma conference call?
How can I listen to the CTI BioPharma earnings call?
What is the focus of CTI BioPharma's research?
What is the conference ID for the CTI BioPharma call?
